Literature DB >> 21855244

Determination of major boswellic acids in plasma by high-pressure liquid chromatography/mass spectrometry.

Kathleen Gerbeth1, Juergen Meins, Simon Kirste, Felix Momm, Manfred Schubert-Zsilavecz, Mona Abdel-Tawab.   

Abstract

Until now, dexamethasone is the medication of choice to reduce peritumoral edema associated with primary and secondary brain tumors. Because of the severe side effects accompanying such a treatment the interest in alternative agents that may be co-administered with glucocorticoids and help to reduce the required dose is constantly increasing. Boswellia serrata gum resin extracts (BSE), which have been designated an orphan drug status by the European Medicines Agency (EMA) in 2002 for the treatment of peritumoral edema, may represent a promising supplemental herbal remedy. However, clinical studies on the effect of BSE on brain edema as well as analyzes of serum levels are very scarce. Based on that background a prospective, placebo controlled, and double blind clinical pilot trial was conducted on 14 patients applying for the first time a high dose of 4200 mg BSE per day and 13 patients receiving placebo. For monitoring the serum levels of all major boswellic acids (BAs) a highly sensitive HPLC-MS method has been developed that allows the determination of KBA and AKBA from 5.0 ng/ml to 3000 ng/ml and of αBA, βBA, AαBA and AβBA from 0.5 ng/ml to 12,000 ng/ml. It is the first validated method that covers such a wide concentration range, which makes it suitable to be used as standard method in clinical trials as it compensates for the great pharmacokinetic variability in the plasma levels of BAs observed in clinical practice. Average steady concentrations (ng/ml) in the range of 6.4-247.5 for KBA, 0-15.5 for AKBA, 36.7-4830.1 for αBA, 87.0-11948.5 for βBA, 73.4-2985.8 for AαBA and 131.4-6131.3 for AβBA were determined in the verum group. The here quantified steady state levels suggest βBA to be a possible candidate for the anti-inflammatory and anti-edemateous effects of BSE. In general, the serum level analysis underlines the promising clinical results of BSE on cerebral edema.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21855244     DOI: 10.1016/j.jpba.2011.07.026

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  6 in total

1.  Protective effects of incensole acetate on cerebral ischemic injury.

Authors:  Arieh Moussaieff; Jin Yu; Hong Zhu; Sebastiano Gattoni-Celli; Esther Shohami; Mark S Kindy
Journal:  Brain Res       Date:  2012-01-09       Impact factor: 3.252

2.  Boswellic acid activity against glioblastoma stem-like cells.

Authors:  Hannah Schneider; Michael Weller
Journal:  Oncol Lett       Date:  2016-05-04       Impact factor: 2.967

3.  Pretreatment with β-Boswellic Acid Improves Blood Stasis Induced Endothelial Dysfunction: Role of eNOS Activation.

Authors:  Mingming Wang; Minchun Chen; Yi Ding; Zhihui Zhu; Yikai Zhang; Peifeng Wei; Jingwen Wang; Yi Qiao; Liang Li; Yuwen Li; Aidong Wen
Journal:  Sci Rep       Date:  2015-10-20       Impact factor: 4.379

Review 4.  Effect of Boswellia species on the metabolic syndrome: A review.

Authors:  Davood Mahdian; Kazem Abbaszadeh-Goudarzi; Amir Raoofi; Ghazaleh Dadashizadeh; Mina Abroudi; Elahe Zarepour; Hossein Hosseinzadeh
Journal:  Iran J Basic Med Sci       Date:  2020-11       Impact factor: 2.699

Review 5.  The Biological Activity of 3-O-Acetyl-11-keto-β-Boswellic Acid in Nervous System Diseases.

Authors:  Yuqing Gong; Xinyi Jiang; Suibi Yang; Yue Huang; Jinhui Hong; Yanxiu Ma; Xin Fang; Yong Fang; Jing Wu
Journal:  Neuromolecular Med       Date:  2022-03-18       Impact factor: 3.843

Review 6.  Considerations to Be Taken When Carrying Out Medicinal Plant Research-What We Learn from an Insight into the IC50 Values, Bioavailability and Clinical Efficacy of Exemplary Anti-Inflammatory Herbal Components.

Authors:  Mona Abdel-Tawab
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.